Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Zhang, Q ^a   Padi, S K R ^a   Tindall, D J ^b   Guo, B ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; HISTONE H3; LYSINE; LYSINE 27; MICRORNA 205; MICRORNA 31; POLYCOMB PROTEIN EZH2; PROTEIN BCL W; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F6; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; HISTONE; MICRORNA; MIRN205 MICRORNA, HUMAN; MIRN31 MICRORNA, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; TAXOID;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; EPIGENETICS; GENE SILENCING; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; BIOLOGICAL MODEL; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHYLATION; PATHOLOGY; PROMOTER REGION; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HISTONES; HUMANS; MALE; METHYLATION; MICRORNAS; MODELS, BIOLOGICAL; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TAXOIDS;

EID: 84928017601     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.454     Document Type: Article

References (43)

1. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 2002; 298: 1039-1043.
2. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-29.
3. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17: 2613-2618.
4. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
5. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV et al. Essential role for activation of the polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006; 5: 1886-1901.
6. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11611.
7. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24: 268-273.
8. Deb G, Thakur VS, Gupta S. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics 2013; 8: 464-476.
9. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010; 116: 5247-5255.
10. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27: 7274-7284.
11. Xie L, Zhang Z, Tan Z, He R, Zeng X, Xie Y et al. MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. Mol Cell Biochem 2014; 392: 153-159.
12. Wang Y, Xiang W, Wang M, Huang T, Xiao X, Wang L et al. Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101. Br J Pharmacol 2014; 171: 618-635.
13. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21: 1050-1063.
14. Wagener N, Holland D, Bulkescher J, Crnković-Mertens I, Hoppe-Seyler K, Zentgraf H et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 2008; 123: 1545-1550.
15. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q et al. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 2010; 17: 801-810.
16. Alimova I, Venkataraman S, Harris P, Marquez VE, Northcott PA, Dubuc A et al. Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer 2012; 131: 1800-1809.
17. Ridinger-Saison M, Evanno E, Gallais I, Rimmelé P, Selimoglu-Buet D, Sapharikas E et al. Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia. Cell Death Differ 2013; 20: 1268-1278.
18. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
19. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-1017.
20. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86.
21. Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, Huang G et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009; 113: 4586-4594.
22. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE et al. A pancreatic isletspecific microRNA regulates insulin secretion. Nature 2004; 432: 226-230.
23. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688.
24. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193-199.
25. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B et al. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010; 1: e105.
26. Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A et al. Polycombmediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell 2012; 21: 121-135.
27. Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 2011; 118: 2830-2839.
28. Yang WW, Wang ZH, Zhu Y, Yang HT. E2F6 negatively regulates ultraviolet-induced apoptosis via modulation of BRCA1. Cell Death Differ 2007; 14: 807-817.
29. Yang WW, Shu B, Zhu Y, Yang HT. E2F6 inhibits cobalt chloride-mimetic hypoxia-induced apoptosis through E2F1. Mol Biol Cell 2008; 19: 3691-3700.
30. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M et al. MiR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009; 69: 2287-2295.
31. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012; 3: 1011-1025.
32. Holland D, Hoppe-Seyler K, Schuller B, Lohrey C, Maroldt J, Dürst M et al. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res 2008; 68: 9964-9972.
33. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006; 97: 484-491.
34. Li K, Liu C, Zhou B, Bi L, Huang H, Lin T et al. Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells. Int J Mol Sci 2013; 14: 11981-11993.
35. Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers ST, Palisaar RJ et al. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol 2013; 43: 307-314.
36. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-1699.
37. Xu Y, An Y, Wang Y, Zhang C, Zhang H, Huang C et al. MiR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 2013; 29: 2019-2024.
38. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM et al. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and posttranscriptional mechanisms. Oncotarget 2011; 2: 669-683.
39. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X,Wang X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
40. Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 2013; 73: 1232-1244.
41. Li X, Liu J, Zhou R, Huang S, Huang S, Chen XM et al. Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation. Br J Haematol 2009.
42. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-112.
43. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ et al. p300 in prostate cancer proliferation and progression. Cancer Res 2003; 63: 7638-7640.